|
Dazed
and confused
With no regulations in sight, low returns and stale product
pipelines, is the anaesthetic drug market facing a dead end?
Aashruti Kak finds out if there is any glimmer left in the
fire
Four
Indian companies sign up with Clinton Foundation
Former US President Bill Clinton recently joined Raymond Chambers,
the first UN Special Envoy on Malaria, and Daniel Vasella,
Chairman and CEO, Novartis, to announce agreements with six
companies for a leading artemisinin-based combination therapy
(ACT).
'Europe
will be the next destination'
Sundeep V Bambolkar, Director-Finance and Operations, Indoco
Remedies, after his recent visit to China is of the view that
post Olympics there shall be a correction in prices of pharmaceutical
intermediates. He offers insight into the company, market
scenario and future trends, in conversation with Arshiya Khan
ICRI
Health to commence two PG diplomas by end 2008
India's healthcare sector has been growing rapidly and it
is estimated that it will be worth $40 billion by 2012, according
to a PriceWaterhouse Cooper report.
FDC
gets US FDA nod for ciprofloxacin solution
FDC has recently got US FDA nod for its abbreviated new drug
application (ANDA), ciprofloxacin ophthalmic solution.
Ranbaxy
wins UK SFO case
Ranbaxy Laboratories announced that the UK Serious Fraud Office's
(SFO) prosecution of its UK subsidiary, Ranbaxy UK Ltd (RUKL),
has been quashed by the English Crown Court.
Glenmark
investing robust amounts in R&D
Glenmark Pharmaceutical is investing huge amount on research
and development activity.
Strides
Arcolab JV enters in-licensing deal with GSK
Strides Arcolab's joint venture (JV) with Onco Therapies Ltd
(OTL), recently signed a licensing and supply agreement with
GlaxoSmithKline (GSK).
Piramal
Healthcare enters dermo-cosmeceuticals
Piramal Healthcare and the Pierre Fabre Group, the second
largest privately owned pharmaceutical group in France, have
jointly launched a new dermo-cosmetic range, Ducray, especially
designed to suit Indian skin and hair.
Sanofi-aventis
to acquire Australia's Symbion Consumer
Recently, Sanofi-aventis entered into a binding agreement
with Primary Health Care for acquiring Symbion CP Holdings
in Australia.
Erica
LifeSciences upgrading R&D centre
Erica LifeSciences is upgrading its existing research and
development (R&D) centre at Kandivali, Mumbai.
Events
Brief
Yagna
for better health
The Arogya International Ayurveda Health Expo-2008 scheduled
for August this year, aims to showcase India as the health
hub of the world by promoting all Indian medical knowledge
systems with special emphasis on ayurveda and its allied sciences.
|
